Physicians' Academy for Cardiovascular Education

Agenda Topics ▼On-demand Online-CME Podcasts News ▼Meeting Reports Slides ▼About

ACC.21 ▼AHA 2020 ▼Covid-19 ▼Diabetes & CVD ▼ESC 2020 ▼HF Practical Tutorials ▼Kidney disease & CVD ▼LDL-c goal attainment in high risk patients ▼

HoFH

Feb. 8, 2015

Share this page with your colleagues and friends:

Continue reading:

4 Things a cardiologist should know about triglycerides

Reducing triglycerides in REDUCE-IT

10' education - Feb. 11, 2020 - Prof. Deepak Bhatt, MD - Online CME

The spectrum of triglyceride-containing lipoproteins

10' education - Feb. 4, 2020 - Jorge Plutzky, MD - Online CME

How can triglycerides increase CV risk?

10' education - Jan. 16, 2020 - Prof. Børge Nordestgaard, MD

5 Things a cardiologist needs to know about GLP-1RA

E-learning 5 Things a cardiologist needs to know about GLP-1 RA

Online-CME - This course consists of 5 lectures.

GLP-1RAs: What are the future directions in development?

10' education - Jan. 6, 2021 - Prof. John Deanfield, MD - Online CME

What is the clinical evidence for the benefits of GLP-1RAs?

10' education - Dec. 10, 2020 - Prof. Subodh Verma, MD - Online CME

5 Things a cardiologist should know about diabetes

Slide Curriculum: Diabetes and cardiology

Slides (curriculum) - July 24, 2018

PACE Special: 5 Things a cardiologist should know about diabetes

Download - Download your free copy

Hypoglycemia in cardiovascular medicine: why worry?

10' education - Mar. 7, 2018 - Prof Guntram Schernthaner - Vienna, Austria - Online CME

ACS

Hypertension stage 1 at early 40s in women associated with increased ACS risk during midlife

Literature - June 22, 2021 - Kringeland E, et al. - Eur J Prev Cardiol 2021

12-Months follow up of rapid hs -TnT protocol in ACS suspected patients

5' education - May 16, 2021 - Prof. Derek Chew, MD, PhD

Concurrent use of DOAC and aspirin without indication associated with increased bleeding in AF and VTE

Literature - May 5, 2021 - Schaefer JK et al. - JAMA Intern Med. 2021

Atherosclerosis

Hb1Ac associated with subclinical atherosclerosis in individuals without diabetes

Literature - July 5, 2021 - Rossello X,, et al. - J Am Coll Cardiol

Two-thirds of ASCVD patients in the US do not reach LDL-c <70 mg/dL after 2 years on LLT

Literature - June 30, 2021 - Cannon CP et al. - JAMA Cardiol. 2021

Redefining intensive LDL-c management in high CV risk patients The case for combination therapy

Agenda - Aug. 27, 2021

Atrial fibrillation

Clinical effects sGC stimulator in HFrEF after a worsening HF event unaffected by AF status

News - July 5, 2021

Myosin activator less effective in patients with HFrEF and AF or atrial flutter

News - July 2, 2021

AF more often detected by implantable vs. external loop recorder after stroke

Literature - June 22, 2021 - Buck BH et al. - JAMA. 2021

BET Inhibition

Effect of BET inhibition on CV outcomes in ACS and diabetes patients

10' education - Dec. 9, 2019 - Prof. Kausik Ray, MD

Primary endpoint not met for BET inhibitor in phase 3 trial

News - Sep. 30, 2019

BET inhibition, an epigenetic pathway: How could BET inhibition modulate atherothrombotic risk?

10' education - Sep. 30, 2019 - Prof. Wouter Jukema

Covid-19

Atypical PF4-dependent thrombosis and thrombocytopenia in some after COVID-19 vaccination

Literature - Apr. 22, 2021 - Scully M, et al. - N Engl J Med. 2021

Clinical resemblance of heparin-induced thrombocytopenia in some cases after COVID-19 vaccination

Literature - Apr. 6, 2021 - Greinacher A et al. - Research Square 2021 (NOT PEER-REVIEWED)

Risk of ischemic stroke in patients hospitalized with COVID-19 in the USA

News - Mar. 19, 2021

Covid-19, ACE2, RAASi

COVID-19, ACE2 and RAAS inhibition

Online-CME - This course consists of 3 parts.

COVID-19, ACE2 and RAAS inhibition

Lecture - Apr. 29, 2020 - Profs. John Deanfield, Jan Danser and Murray Epstein

COVID-19, ACE2 and RAASi - a scientific perspective

10' education - Apr. 19, 2020 - Prof. Jan Danser, PhD

CV Inflammation

IL-6 levels in the general population associated with new-onset HFpEF

Literature - June 28, 2021 - Chia YC et al. - J Am Heart Assoc. 2021

Biomarkers of inflammation predict HF hospitalization and adverse outcomes in AF

Literature - June 14, 2021 - Benz AP, et al. - J Am Heart Assoc. 2021

Novel IL-6 inhibitor largely reduces hsCRP in CKD with elevated hsCRP

News - May 19, 2021

CVRM

Tackling residual risk beyond LDL-c therapy: The emerging role of EPA & triglycerides

Agenda - Aug. 29, 2021

The role for primary care in reducing CV risk in diabetes

10' education - Oct. 20, 2020 - Prof. Richard Hobbs, MD - Online CME

The mechanism of action of bempedoic acid

Diabetes

T2DM-related microvascular disease associated with incident HF

Literature - July 27, 2021 - Kaze AD, et al. - J Am Heart Assoc. 2021

Where do GLP-1RA fit in in current and future management of CKD?

10' education - July 26, 2021 - Frederik Persson, MD - Online CME

Treatment goals for patients with T2DM and CKD

10' education - July 13, 2021 - Prof. Peter Rossing, MD - Online CME

Diabetes & CVD

T2DM-related microvascular disease associated with incident HF

Literature - July 27, 2021 - Kaze AD, et al. - J Am Heart Assoc. 2021

Where do GLP-1RA fit in in current and future management of CKD?

10' education - July 26, 2021 - Frederik Persson, MD - Online CME

Treatment goals for patients with T2DM and CKD

10' education - July 13, 2021 - Prof. Peter Rossing, MD - Online CME

Epigenetics in CVD

Effect of BET inhibition on CV outcomes in ACS and diabetes patients

10' education - Dec. 9, 2019 - Prof. Kausik Ray, MD

BET inhibitor therapy did not meet primary endpoint of reducing MACE in post-ACS patients with T2DM

News - Nov. 17, 2019

Clinical update on BET inhibition: The patient profile that may benefit from BET inhibition

10' education - Aug. 31, 2019 - Prof. Kausik Ray, MD

ESC Diabetes guidelines 2019

Slides: 2019 ESC guidelines on diabetes, pre-diabetes and cardiovascular diseases - Expert insights and rationale

Slides (presentation) - Oct. 7, 2019 - Prof Francesco Cosentino, MD, Stockholm, Sweden - CME symposium held during ESC 2019

The 2019 ESC/EASD diabetes guidelines: a major paradigm shift in the management of T2DM

10' education - Sep. 30, 2019 - Paris, France - Prof. Francesco Cosentino, MD

New ESC/EASD Guidelines on diabetes no longer regard metformin as first-line therapy

News - Sep. 3, 2019

ESC/EAS Guidelines dyslipidaemias 2019

LDL-c targets in the ESC/EAS dyslipidaemia guidelines in a nutshell

10' education - Oct. 4, 2019 - Prof. Brian Ference, MD

Slides: LDL-c targets in the ESC/EAS dyslipidaemia guidelines in a nutshell

Slides (presentation) - Sep. 9, 2019 - ESC Paris, France - Prof. Brian A. Ference, M.D, University of Cambridge, United Kingdom - CME symposium held during ESC 2019

Rationale for the lower LDL-c targets in the 2019 ESC/EAS Dyslipidemia Guidelines

5' education - Sep. 9, 2019 - Paris, France - Prof. François Mach

Expert Meeting GLP-1, CVD & T2DM

Translation of novel approaches in CVD & diabetes to clinical practice

10' education - Mar. 22, 2018 - John Deanfield, Francesco Cosentino, Filip Knop - Online CME

Novel diabetes drugs in clinical management: Extending the opportunities

10' education - June 5, 2018 - Stefano Taddei, Cees Tack, Massimo Volpe - Online CME

Clinical trials in diabetes and CVD: What did we learn?

10' education - Mar. 22, 2018 - Filippo Crea, Angelyn Bethel, Eduard Montanya - Online CME

Familial Hypercholesterolemia

Statin therapy during pregnancy?

5' education - June 9, 2021 - Prof. Maciej Banach, PhD, MD

Increased atherogenicity of LDL and impaired HDL function in children with FH

News - June 7, 2021

Real-world data of PCSK9i use in FH patients

News - June 2, 2021

German videos

Möglichkeiten in der Lipidtherapie die unabhängig vom LDL-c das residuale Risiko reduzieren

Residuales Risiko: Die Rolle der Hypertriglyceridämie

Global Heart Failure Academy education on ReachMD

Common misconceptions about iron deficiency in heart failure and what to do about it

Clinical implications of managing iron deficiency from AFFIRM-AHF

AHA 2020: New Insights on Iron Deficiency and Heart Failure

GLP-1 RA & CVD

Where do GLP-1RA fit in in current and future management of CKD?

10' education - July 26, 2021 - Frederik Persson, MD - Online CME

How can GLP-1RA benefit a patient with diabetes and CKD?

10' education - July 1, 2021 - Daniël van Raalte, MD, PhD - Online CME

Prevention strategies in patients with CKD and T2DM

10' education - June 24, 2021 - Ofri Mosenzon, MD - Online CME

Heart Failure

Phenotypic clusters in HFpEF

5' education - July 28, 2021 - Alicia Uijl, PhD

T2DM-related microvascular disease associated with incident HF

Literature - July 27, 2021 - Kaze AD, et al. - J Am Heart Assoc. 2021

Suboptimal use of evidence-based medical therapies in patients with HFrEF and CKD

Literature - July 14, 2021 - Patel RB et al. - J Am Coll Cardiol. 2021

HFpEF: The essentials to know

HFpEF: Current and future clinical approaches to manage HFpEF

10' education - Aug. 27, 2018 - Burkert Pieske, MD - Berlin, Germany - Online CME

Slides: HFpEF: What are the most likely pathophysiological mechanisms involved in the disease

Slides (presentation) - Aug. 27, 2018 - Carolyn Lam, MD - Singapore

HFpEF: How to diagnose

10' education - Aug. 27, 2018 - Barry Borlaug - Rochester, MN, USA - Online CME

Hypertension

Hypertension stage 1 at early 40s in women associated with increased ACS risk during midlife

Literature - June 22, 2021 - Kringeland E, et al. - Eur J Prev Cardiol 2021

Larger SBP reduction by renal denervation in resistant hypertension patients on combination pill

News - May 17, 2021

Scientifc Statement on adverse pregnancy outcomes and CVD

Literature - Apr. 21, 2021 - Parikh NI et al. - Circulation. 2021

Inflammation Expert Opinions

Ultime notizie sulla terapia: Un farmaco anti-infiammatorio riduce eventi cardiovascolari maggiori

5' education - Aug. 27, 2017 - ESC 2017, Barcelona, Spain

Breakthrough therapy: Anti-inflammatory drug can affect important CV outcomes

5' education - Aug. 27, 2017 - ESC 2017, Barcelona, Spain

Clinical implications of inhibiting inflammation as risk factor for progression of CVD

5' education - Aug. 27, 2017

Invest in your arteries

Estimating CV risk and treatment benefit

10' education - June 12, 2018 - Prof. Frank Visseren - Utrecht, The Netherlands - Online CME

Importance of hypertension in CVD prevention

10' education - June 12, 2018 - Prof. Richard Hobbs - Oxford, UK - Online CME

The role of lipids in CVD prevention: Lessons learned about statins

10' education - June 6, 2018 - Prof. Kees Hovingh - Amsterdam, The Netherlands - Online CME

Kidney disease & CVD

Where do GLP-1RA fit in in current and future management of CKD?

10' education - July 26, 2021 - Frederik Persson, MD - Online CME

Suboptimal use of evidence-based medical therapies in patients with HFrEF and CKD

Literature - July 14, 2021 - Patel RB et al. - J Am Coll Cardiol. 2021

Treatment goals for patients with T2DM and CKD

10' education - July 13, 2021 - Prof. Peter Rossing, MD - Online CME

LDL-c Key Lessons

Key lessons on LDL-c and CV risk

LDL-c Key lessons

Screening for familial hypercholesterolemia after ACS pays off

LDL-c Key Lessons

LDL-c lowering treatment impacts disease progression before clinical manifestation

LDL-c Key Lessons

Lipids

Two-thirds of ASCVD patients in the US do not reach LDL-c <70 mg/dL after 2 years on LLT

Literature - June 30, 2021 - Cannon CP et al. - JAMA Cardiol. 2021

Tackling residual risk beyond LDL-c therapy: The emerging role of EPA & triglycerides

Agenda - Aug. 29, 2021

Sustained CV benefits of statin treatment after discontinuation

Literature - May 12, 2021 - Bosch J et al. - Eur Heart J. 2021

Lp(a)

Registry study shows large reduction of clinical outcomes by lipoprotein apheresis

News - June 3, 2021

Elevated Lp(a) associated with large artery atherosclerosis stroke and risk of recurrent stroke

Literature - Mar. 23, 2021 - Arnold M et al. - Eur Heart J. 2021

Elevated Lp(a) associated with CAD in individuals without a family history of CVD

Literature - Mar. 8, 2021 - Finneran P et al. - J Am Heart Assoc. 2021

PCSK9

Two-thirds of ASCVD patients in the US do not reach LDL-c <70 mg/dL after 2 years on LLT

Literature - June 30, 2021 - Cannon CP et al. - JAMA Cardiol. 2021

Redefining intensive LDL-c management in high CV risk patients The case for combination therapy

Agenda - Aug. 27, 2021

Real-world data of PCSK9i use in FH patients

News - June 2, 2021

Pulmonary Arterial Hypertension

Why cardiologists should be more interested in PAH

3' education - Mar. 9, 2018 - VBWG at ACC, Orlando, FL, USA - Prof. Mardi Gomberg-Maitland, Falls Church, VA, USA - Online CME

Novel insights in the management and prognosis of pulmonary hypertension

5' education - Aug. 29, 2017 - ESC 2017, Barcelona, Spain - Prof Nazzareno Galiè - Bologna, Italy

Low-risk profile in pulmonary arterial hypertension patients predicts better survival

Literature - June 6, 2017 - Kylhammar D, et al. - Eur Heart J 2017

SGLT2i

Treatment goals for patients with T2DM and CKD

10' education - July 13, 2021 - Prof. Peter Rossing, MD - Online CME

E-learning SGLT2i in CKD: How to overcome clinical inertia?

Online-CME - This course consists of 3 parts.

Phase III trial with SGLT2 inhibitor meets primary endpoint in HFpEF

News - July 6, 2021

siRNA therapy and LDL-C

Safety of PCSK9 siRNA demonstrated in pooled data analysis

News - June 1, 2021

Pooled analysis of three trials with PCSK9 siRNA in patients with HeFH or ASCVD

Literature - Apr. 20, 2021 - Wright RS et al. - J Am Coll Cardiol. 2021

The gap between guideline LDL-c goals and current practice: How are we doing?

15' education - Apr. 1, 2021 - Prof. François Mach, MD and prof. Erik Stroes, MD, PhD - Online CME

Stroke

AF more often detected by implantable vs. external loop recorder after stroke

Literature - June 22, 2021 - Buck BH et al. - JAMA. 2021

Head-to-head comparison of risk scores for ischemic stroke in patients with AF and CKD

5' education - June 14, 2001 - Ype de Jong, MD

Comparable effectiveness of low-dose and regular-strength aspirin in patients with ASCVD

News - May 16, 2021

Triglycerides

Tackling residual risk beyond LDL-c therapy: The emerging role of EPA & triglycerides

Agenda - Aug. 29, 2021

Omega-3 fatty acids supplementation associated with increased risk of incident AF

Literature - June 15, 2021 - Lombardi M et al. - Eur Heart J Cardiovasc Pharmacother. 2021

Icosapent ethyl reduces whole-heart coronary atherosclerotic plaque burden

News - May 31, 2021

© 2006 - 2021 pace-cme.org - About